Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials

In this retrospective study of two large phase III studies of patients with metastatic castration-resistant prostate cancer, abiraterone acetate conferred benefit to patients regardless of Gleason score (<8 versus ≥8) at initial diagnosis.

from Cancer via xlomafota13 on Inoreader http://ift.tt/1XutFSe
via IFTTT